Synopsis
This conference has now passed. Join us in Nassau, The Bahamas in 2019 for the 3rd series, view details here. Alternatively, the following meetings may be of interest;
3rd DNA Replication/Repair Structures and Cancer | 11-15 February 2018 | Cancun, Mexico
DNA & Interacting Proteins as Single Molecules - In Vitro and In Vivo | 21-24 February 2018 | Cancun, Mexico
Defect in DNA damage repair and checkpoint control is the underlying mechanism for tumorigenesis, since it allows the accumulation of multiple genetic alternations, which are essential for the initiation of tumorigenesis. This has been clearly illustrated to be the cause of several human cancer-prone syndromes and also revealed by recent human genome studies. On the other hand, defective DNA repair and checkpoint activation also make cancer cells more vulnerable for particular DNA damaging agents or inhibitors that specifically disrupt some of these checkpoint pathways. With the increasing understanding of defects in DNA repair and checkpoint control in tumorigenesis, there are extensive interests in exploring these deficiencies, especially taking advantage of the synthetic lethality concept and targeting particular DNA repair and checkpoint pathways for cancer therapy. The purpose of this conference is to bring together basic, translational and clinical investigators and discuss the current and future directions, opportunities and obstacles in the development of these anti-cancer modalities and how to best apply these concepts in clinical practice.
Key Sessions
- Highlight recent advances in the field of DNA damage repair
- Identify novel targets in DNA repair and checkpoint pathways
- Explore the concept of synthetic lethality for cancer treatment
- Assess the therapeutic potential of new anti-cancer modalities
- Learn mechanisms of therapeutic resistance and ways to improve cancer therapy
Target Audience
This conference explores topics that should appeal to basic, translational and clinical investigators as well as clinicians ranging from academics to industry. The audience will benefit greatly from the interactions with experts in the fields of DNA damage response, drug development and clinical trials.
2017 DNA Poster Prize
The conference chairs will be awarding 3 poster prizes for the best poster display and presentation. To be in with a chance of winning, submit your poster by 08 December 2016. The winners will be selected shortly after the Poster Session and each winner will receive $250!
Confirmed Invited Speakers
Christopher Bakkenist (University of Pittsburgh)
Michelle Barton (MD Anderson Cancer Center)
Lauren Averett Byers (MD Anderson Cancer Center)
Dipanjan Chowdhury (Dana-Farber Cancer Institute)
Karlene Cimprich (Stanford University)
Giulio Draetta (MD Anderson Cancer Center)
Daniel Durocher (The Lunenfeld-Tanenbaum Research Institute)
Yi Fan (University of Pennsylvania)
Shridar Ganesan (Rutgers Cancer Institute of New Jersey)
Jean Gautier (Columbia University)
Reuben Harris (University of Minnesota)
Robert Hromas (University Of Florida)
Jos Jonkers (Netherlands Cancer Institute)
Chuan-Yuan Li (Duke University Medical Center)
Zhenkun Lou (Mayo Clinic)
KyungJae Myung (Institute for Basic Science)
Jac A. Nickoloff (Colorado State University)
Mark J O'Connor (AstraZeneca)
Akihiro Ohashi (Takeda)
Yves Pommier (NCI)
Brendan Price (Dana-Farber Cancer Institute)
Elizabeth Swisher (University of Washington)
Lorraine Symington (Columbia University)
Yinsheng Wang (UC Riverside)
Matthew Weitzman (The Children’s Hospital of Philadelphia)
Richard Wood (MD Anderson Cancer Center)
Fen Xia (UAMS)
Sponsors
Report
This 2nd major conference on Target DNA repair for Cancer Therapy took place in Cancun, Mexico from 27 February to 02 March 2017. The conference attracted many leaders in the field of DNA damage repair. It also drew attendance of scientists working in pharmaceutical and biotech companies that are developing and testing new compounds that target DNA repair and DNA damage checkpoint pathways for cancer treatment. Moreover, this conference was also attended by several physicians who are conducting clinical trials using various DNA repair and checkpoint inhibitors. The convergence of interests from academic, industry, and clinic makes this a unique conference that enjoyed by all the attendees.
The conference was chaired by Dr. Helen Piwnica-Worms (Vice Provost, Science, The University of Texas MD Anderson Cancer Center) and Dr. Junjie Chen (Professor and Chain, Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center).
Faculty attended included Dr. Karlene Cimprich (Stanford University), Dr. Jean Gautier (Columbia University), Dr. Dipanjan Chowdhury (Dana Farber Cancer Institute), Dr. Jingsong Yuan (Columbia University), Dr. Lorraine Symington (Columbia University), Dr. Zhenkun Lou (Mayo Clinic), Dr. Nima Mosammaparast (Washington University at St. Louis), Dr. Robert A. Hromas (University of Florida), Dr. Eli Rothenberg (New York University), Dr. Yinsheng Wang (University of California Riverside), Dr. Mark J. O’Connor (AstraZeneca), Dr. Akihiro Ohashi (Takeda), Dr. Giulio Draetta (MD Anderson Cancer Center), Dr. Lauren Byers (MD Anderson Cancer Center), Dr. Laura Butler (Atrin Pharmaceuticals), Dr. Philip Hinds (Tufts University), Dr. Elizabeth Swisher (University of Washington), Dr. Yi Fan (University of Pennsylvania), Dr. Shridar Ganesan (Rutgers Cancer Institute of New Jersey), Dr. Guang Peng (MD Anderson Cancer Center), Dr. Mien-Chie Hung (MD Anderson Cancer Center), Dr. Michelle Barton (MD Anderson Cancer Center), Sudhakar Jha (Cancer Science Institute of Singapore), Dr. Brendan Price (Dana Farber Cancer Institute), Dr. David Yu (Emory University), Dr. Jac A. Nickoloff (Colorado State University), Dr. Jos Jonkers (Netherlands Cancer Institute), Dr. Kyungjae Myung (Institute of Basic Sciences, Korea), Dr. Richard Pomerantz (Temple University), Dr. Chuan-Yuan Li (Duke University), Dr. Reuben Harris (University of Minnesota), Dr. Matthew Weitzman (Children’s Hospital of Philadelphia), Dr. Katharina Schlacher (MD Anderson Cancer Center), Dr. Ranjit Bindra (Yale School of Medicine), Dr. Daniel Durocher (Lunenfeld-Tanenbarum Research Institute), Dr. Chris Bakkenist (University of Pittsburgh), Dr. Yves Pommier (NIH/NCI), Dr. Fen Xia (University of Arkansas for Medical Science), and Dr. Eric Hendrickson (University of Minnesota).
The conference emphasized on several ongoing and new areas in the field of DNA damage response, which include: 1) mechanisms underlying DNA repair choice, 2) new signaling molecules and pathways involved in DNA damage response, 3) novel technologies and approaches for studying DNA repair processes, 4) translesion DNA synthesis, 5) APOBEC family proteins in mutagenesis and cancer evolution, 5) conflict of transcription and DNA replication, 6) synthetic lethality approaches for the identification of new agents that target DNA repair defects and pathways. Several additional areas covered by this conference are: a) stem cell biology, b) epigenetic and chromatin regulations, c) oncogenic signaling pathways, d) oncometabolites, e) immune checkpoints. These new topics reflect the expansion of the field, which goes way beyond DNA repair and cell cycle checkpoint control. The industry presentations focused on the newly developed ATR, WEE1, and CDC7 inhibitors in clinical trials and the potential combinatory therapies using these checkpoint and cell cycle inhibitors. Several physician scientists discussed the results, promises, and challenges of using these checkpoint and other DNA repair inhibitors for the clinical management of cancer patients.
The conference was highly interactive, with extensive discussions at the Q&A and poster sessions. New ideas and collaborations were established. More importantly, besides large pharmaceutical companies such as AstraZeneca and Takeda, small companies like Atrin were also present at the meeting. In addition, there were discussions about new companies formed that focus on developing checkpoint and DNA repair inhibitors. Thus, with the expansion of the field and novel compounds that target various DNA repair and other pathways that may come on board in the near future, we anticipate that the next conference will bring together leaders from several disciplines and accelerate the development of new agents for cancer treatment. _____________________________________
The meeting was expertly organized and supported by Fusion Conferences, Ltd. The University of Texas MD Anderson Cancer Center generously and enthusiastically supported the meeting in many ways and the generous support of Pfizer and Genomic Vision is also gratefully appreciated.
Programme
MONDAY 27TH FEBRUARY 2017 |
||
14:00 – 14:45 |
Registration & Reception |
|
14:00 – 14:45 |
Welcome Lunch |
|
14:45 – 15:00 |
Opening Comments |
|
MECHANISMS OF GENOME MAINTENANCE |
||
15:00 – 15:30 |
Karlene Cimprich |
WHEN RNA MEETS DNA: DANGEROUS LIAISONS IN THE GENOME |
15:30 – 16:00 |
Jean Gautier |
MOVING DNA DOUBLE-STRAND BREAKS |
16:00 – 16:30 |
Dipanjan Chowdhury |
TIRR MASKS THE HISTONE METHYL-LYSINE BINDING FUNCTION OF 53BP1 TO REGULATE ITS ACTIVITY |
16:30 – 17:00 |
Jingsong Yuan |
RPA-BINDING PROTEIN ETAA1 PARTICIPATES IN THE ACTIVATION OF ATR SIGNALING PATHWAY IN RESPONSE TO DNA REPLICATION STRESS |
17:00 – 17:30 |
Lorraine Symington |
DNA END RESECTION AND REPAIR PATHWAY CHOICE |
17:30 – 18:00 |
Refreshments |
|
18:00 – 18:30 |
Zhenkun Lou |
UFMYLATION SIGNALLING IN THE DNA DAMAGE RESPONSE |
18:30 – 18:45 |
Nima Mosammaparast Washington University in St. Louis |
A UBIQUITIN-DEPENDENT SIGNALING AXIS SPECIFIC FOR ALKYLATION DAMAGE REPAIR |
18:45 – 19:00 |
Wei Zhang |
SELECTIVE MODULATION OF HUMAN E3 LIGASES AND DEUBIQUITINASES FOR CANCER THERAPY BY ENGINEERED UBIQUITIN VARIANTS |
19:00 – 19:30 |
Robert A Hromas |
THE ENDONUCLEASE EEPD1 IS A GATEKEEPER FOR 5’ END RESECTION FOR HOMOLOGOUS RECOMBINATION AND RESCUE OF STRESSED REPLICATION FORKS |
19:30 – 19:45 |
Eli Rothenberg New York University School of Medicine |
SPATIOTEMPORAL DYNAMICS OF THE INTERNAL ORGANIZATION OF INDIVIDUAL DSB REPAIR FOCI |
19:45 – 20:15 |
Yinsheng Wang UC Riverside |
POST-TRANSLATIONAL REGULATIONS OF REPAIR OF INTERSTRAND CROSS-LINK LESIONS AND DNA DOUBLE-STRAND BREAKS |
20:15 |
Dinner at Leisure |
TUESDAY 28TH FEBRUARY 2017 |
||
07:00 – 08:30 |
Breakfast *Kalmia Buffet Restaurant* |
|
EMERGING CONCEPTS IN TARGETED THERAPIES |
||
08:30 – 09:00 |
Mark J O'Connor |
EXPLOITING CANCER REPLICATION STRESS USING PHARMACOLOGICAL INHIBITORS OF ATR AND WEE1 |
09:00– 09:30 |
Akihiro Ohashi Takeda |
A NOVEL CDC7-SELECTIVE INHIBITOR TAK-931 WITH POTENT ANTITUMOR ACTIVITY |
09:30 – 10:00 |
Giulio Draetta |
CRITICAL VULNERABILITIES OF PANCREATIC CANCER CELL SUBPOPULATIONS
|
10:00 – 10:45 |
Refreshments & Group Photo |
|
10:45 – 11:15 |
Lauren Averett Byers |
TARGETING DNA DAMAGE RESPONSE (DDR) FOR THE TREATMENT OF LUNG CANCER
|
11:15 – 11:30 |
Laura Butler |
POTENT AND SELECTIVE ATR INHIBITORS FOR THE TREATMENT OF HOMOLOGOUS-RECOMBINATION DEFICIENT AND PARPi-RESISTANT CANCERS |
11:30 – 12:00 |
Philip Hinds |
TARGETING SENESCENCE AS A TUMOR PROMOTER IN CELLS WITH DEFECTIVE DDR OR REPLICATION STRESS |
12:00 – 12:15 |
Naoaki Fujii
|
DISCOVERY OF SMALL MOLECULE INHIBITORS TARGETING THE TRANSLESION DNA SYNTHESIS MACHINERY |
12:15 – 16:15 |
Lunch at Leisure & Free Time |
|
CLINICAL EXPLORATION OF DEFECTS IN DNA DAMAGE CHECKPOINT AND DNA REPAIR |
||
16:15 – 16:45 |
Elizabeth Swisher |
DNA THERAPIES FOR OVARIAN CANCER AND PREDICTORS OF RESPONSE AND RESISTANCE |
16:45 – 17:15 |
Yi Fan University of Pennsylvania |
DNA-PK-MEDIATED THERAPY RESISTANCE IN CANCER STEM CELLS |
17:15 – 17:45 |
Shridar Ganesan |
PROTEIN (LYSINE) METHYLTRANSFERASES G9A AND GLP1 PROMOTE RESPONSES TO DNA DAMAGE |
17:45 – 18:15 |
Guang Peng
|
DYSFUNCTIONAL UBIQUITINATION PROCESS GENERATES A THERAPEUTIC VULNERABILITY IN ARID1A-DEFICIENT CANCERS FOR DNA DAMAGE CHECKPOINT INHIBITORS |
18:15 – 18:45 |
Mien-Chie Hung |
MARKER-GUIDED COMBINATION THERAPY WITH PARP INHIBITORS |
18:45 – 19:30 |
Poster Session & Refreshments |
|
19:30 |
Dinner at Leisure |
WEDNESDAY 1ST MARCH 2017 |
||
07:00 – 08:30 |
Breakfast *Kalmia Buffet Restaurant* |
|
CHROMATIN BIOLOGY AND DNA DAMAGE RESPONSE |
||
08:30 – 09:00 |
Michelle Barton |
TRIM24: AN INTERSECTION BETWEEN P53 REGULATION AND EPIGENETIC FUNCTION |
09:00 – 09:15 |
Sudhakar Jha |
ROLE OF RVBS IN MAINTAINING TIP60.COM’S OPTIMAL ACTIVITY FOR DNA DAMAGE RESPONSE |
09:15 – 09:45 |
Brendan Price |
CHROMATIN DYNAMICS, EPIGENETICS AND THE REPAIR OF DNA BREAKS |
09:45 – 10:15 |
Refreshments |
|
10:15 – 10:30 |
David Yu |
EXPLOITING A NOVEL ROLE FOR SAMHD1 IN DNA END RESECTION FOR DISCRIMINATING RADIATION VS CHEMOTHERAPY RESISTANCE FOR PERSONALIZING CANCER THERAPY |
10:30 – 11:00 |
Jac A. Nickoloff |
NUCLEASES AND SIGNALING PATHWAYS IN REPLICATION STRESS RESPONSES |
11:00 – 11:30 |
Jos Jonkers |
GENETIC DISSECTION OF TUMOR DEVELOPMENT, THERAPY RESPONSE AND RESISTANCE IN MOUSE MODELS OF BRCA-DEFICIENT BREAST CANCER |
11:30 – 12:00 |
Kyungjae Myung |
A NOVEL CHEMOTHERAPEUTIC AGENT TO TREAT TUMORS WITH DNA MISMATCH REPAIR DEFICIENCIES |
12:00 – 16:15 |
Lunch at Leisure & Free Time |
|
ARISING TOPICS IN GENOME MAINTENANCE |
||
16:15 – 16:45 |
Richard Wood |
DNA POLYMERASES WITH DISTINCT MECHANISMS FOR MAINTAINING CHROMOSOME STABILITY
|
16:45 – 17:00 |
Richard Pomerantz |
DNA POLYMERASE Θ SPECIALIZES IN INCORPORATING SYNTHETIC EXPANDED-SIZE (XDNA) NUCLEOTIDES |
17:00 – 17:30 |
Daniel Durocher |
PROSPECTIVE IDENTIFICATION OF VULNERABILITIES TO DNA REPAIR INHIBITORS |
17:30 – 18:00 |
Reuben Harris |
MUTAGENESIS BY APOBEC3 ENZYMES IN CANCER |
18:00 – 18:30 |
Matthew Weitzman |
APOBEC3A SENSITIZES CANCER CELLS TO CHECKPOINT INHIBITORS |
18:30 – 18:45 |
Katharina Schlacher |
TP53 PROMOTES GENOMIC STABILITY AND REPLICATION PATHWAY HOMEOSTASIS BY EPIGENETICS-ENABLED MRE11 REPLICATION RESTART |
18:45 – 19:00 |
Ranjit Bindra |
ONCOMETABOLITES INDUCE A BRCANESS STATE THAT CAN BE EXPLOITED BY PARP INHIBITORS |
19:00 – 20:00 |
Poster Session & Refreshments |
|
20:15 |
*Gala Dinner & Poster Awards* |
THURSDAY 2ND MARCH 2017 |
||
07:00 – 08:30 |
Breakfast *Kalmia Buffet Restaurant* |
|
DEVELOPING IDEAS IN CANCER TREATMENT |
||
08:30 – 09:00 |
Chuan-Yuan Li |
DNA DOUBLE STRAND BREAKS INDUCED BY SUBLETHAL ACTIVATION OF APOPTOTIC CASPASES AND THEIR ROLES IN CARCINOGENESIS AND TUMOUR GROWTH |
09:00 – 09:30 |
Chris Bakkenist University of Pittsburg |
DNA DAMAGE SIGNALING TO IMMUNE CHECKPOINTS |
09:30 – 10:00 |
Yves Pommier |
TOPOISOMERASE CLEAVAGE COMPLEXES AND GENOMIC STABILITY |
10:00 – 10:30 |
Refreshments |
|
10:30 – 11:00 |
Fen Xia |
IONIZING RADIATION-INDUCED SYNTHETIC LETHALITY OF PARP INHIBITION IN BRCA1-PROFICIENT CANCER CELLS DEPENDS ON P53 |
11:00 – 11:30 |
Eric A. Hendrickson |
THE ROLES OF DNA LIGASES IN CHROMOSOMAL TRANSLOCATIONS AND TELOMERE FUSIONS |
11:30 – 11:45 |
Olimpia Alessandra Buoninfante |
A NOVEL SYNTHETIC LETHALITY IN THE DDT NETWORK: STRATEGIES FOR PRECISION CANCER THERAPY |
11:45 – 12:00 |
Closing Comments |
Speakers
Invited Speakers
- Prof. Lorraine Symington
Professor, Columbia University - Professor Karlene Cimprich
Professor, Stanford University - Prof. Reuben Harris
Professor, University of Minnesota - Prof. Dr. Robert Hromas
Professor and Chair, University of Florida - Prof. Jac Nickoloff
Professor and Head, Colorado State University - Dr. Lauren Byers
Assistant Professor, The University of Texas MD Anderson Cancer Center - Dr. Yves Pommier
Branch Chief, National Cancer Institute, NIH - Dr. Giulio Draetta
Professor, UT MD Anderson Cancer Center - Prof. Dipanjan Chowdhury
Associate Professor, Dana-Farber Cancer Institute (Harvard Medical School) - Dr. Daniel Durocher
Senior Scientist, Lunenfeld-Tanenbarum Research Institute, Sinai Health System - Prof. Dr. Elizabeth Swisher
Professor, University of Washington - Dr. Mark O'Connor
Chief Scientist, AstraZeneca - Prof. Zhenkun Lou
Professor, Mayo Clinic - Dr. Brendan Price
Professor, Dana-Farber Cancer Institute - Prof. Richard Wood
Professor, The University of Texas MD Anderson Cancer Center - Dr. Shridar Ganesan
Associate Professor, Rutgers Cancer Institute of New Jersey - Dr. Yi Fan
Assistant Professor, University of Pennsylvania - Dr. Michelle Barton
Dean, UT MD Anderson Cancer Center - Dr. Jean Gautier
Professor, Columbia University Medical Center - Dr. Akihiro Ohashi
Group Head, Takeda Pharmaceutical Company Limited - Dr. Guang Peng
Assistant Professor, MD Anderson Cancer Center - Dr. Matthew Weitzman
Associate Professor, Children's Hospital of Philadelphia - Prof. Chuan-Yuan Li
Professor, Duke University Medical Center - Prof. Mien-Chie Hung
Vice President for Basic Research, MD Anderson Cancer Center - Dr. Yinsheng Wang
Professor, University of California Riverside - Dr. Fen Xia
Professor and Chair, University of Arkansas for Medical Sciences - Prof. Jos Jonkers
Division Head, Netherlands Cancer Institute - Prof. Philip Hinds
Professor and Chair, Tufts University School of Medicine - Prof. Kyungjae Myung
Director, Institute of Basic Science - Dr. Ranjit Bindra
Associate Professor, Yale Medical School - Prof. Christopher Bakkenist
Associate Professor, University of Pittsburgh School of Medicine - Prof. Eric Hendrickson
Professor, University of Minnesota
Feedback
Sign In
Your feedback has been received.
Cant see images? See gallery on Flickr